{"DataElement":{"publicId":"2737648","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia Etiology Type","preferredDefinition":"A description of the therapy related acute myeloid leukemia etiology.","longName":"TX_AML_ETLGY_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2737640","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia Etiology","preferredDefinition":"An acute myeloid leukemia arising as a result of the mutagenic effect of alkylating agents and/or ionizing radiation.  (WHO, 2001)_The cause of a disease.","longName":"TX_AML_ETLGY","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2648235","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia","preferredDefinition":"An acute myeloid leukemia arising as a result of the mutagenic effect of alkylating agents and/or ionizing radiation.  (WHO, 2001) -- 2003","longName":"C8252","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Post Cytotoxic Therapy","conceptCode":"C8252","definition":"An acute myeloid leukemia arising as a result of the mutagenic effect of chemotherapy agents and/or ionizing radiation.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"324FF521-963C-5A87-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-07","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-06-07","modifiedBy":"ONEDATA","dateModified":"2007-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2512801","version":"1","preferredName":"Etiology","preferredDefinition":"The cause of a disease.","longName":"C16390","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etiology","conceptCode":"C16390","definition":"The cause of a disease or abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B8A7E81-FDBA-3170-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"COOPERM","dateModified":"2016-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49804516-5AEE-3ACF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2737643","version":"1","preferredName":"Therapy Related Malignant Neoplasm Etiology Type","preferredDefinition":"The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself._The cause of a disease._Type; a subdivision of a particular kind of thing.","longName":"TX_MLGNT_NPLM_ET_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"36","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497F9A00-EA76-4A70-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Topoisomerase II inhibitor-related","valueDescription":"Topoisomerase-II Inhibitor Related","ValueMeaning":{"publicId":"2737644","version":"1","preferredName":"Topoisomerase-II Inhibitor Related","longName":"2737644","preferredDefinition":"Substances that either stabilize DNA-protein complexes damaging DNA (e g., teniposide), or those that inhibit the catalytic activity of the enzyme (e.g., merbarone, ICRF-187). Despite their differences in action, these agents all block cells in G2/M: Related; connected or associated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase-II Inhibitor","conceptCode":"C1968","definition":"Any substance that inhibits topoisomerase-II, a topoisomerase that relieves torsional stress in a DNA molecule by cutting both strands of the DNA double helix. A topoisomerase II inhibitor can either stabilize the DNA-protein complex or inhibit the catalytic activity of the enzyme. Inhibition of topoisomerase-II causes DNA damage, inhibition of DNA replication, and apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497F9A00-EA85-4A70-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497F9A00-EA9E-4A70-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"},{"value":"Alkylating agent / radiation-related","valueDescription":"Alkylating Agent Radiation Therapy Related","ValueMeaning":{"publicId":"2737646","version":"1","preferredName":"Alkylating Agent Radiation Therapy Related","longName":"2737646","preferredDefinition":"Agents that replace hydrogen atom(s) in biologically active molecules with alky radical(s), hindering proper function.  Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cell growth.: use PHOTOTHERAPY, LASER THERAPY, or ULTRAVIOLET THERAPY for therapeutic radiation with visible, laser, or ultraviolet light, respectively.: Related; connected or associated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkylating Agent","conceptCode":"C223","definition":"Agents that replace hydrogen atom(s) in biologically active molecules with alky radical(s), hindering proper function.  Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Relationship","conceptCode":"C25648","definition":"A state of connectedness between people, objects, or events; to be associated or connected with something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497F9A00-EAAF-4A70-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"497F9A00-EAC8-4A70-E044-0003BA3F9857","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"ALEYR","dateModified":"2008-03-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2737642","version":"1","preferredName":"Therapy Related Malignant Neoplasm Etiology Type","preferredDefinition":"The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.:The cause of a disease.:Type; a subdivision of a particular kind of thing.","longName":"C4969:C16390:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy-Related Malignant Neoplasm","conceptCode":"C4969","definition":"The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Etiology","conceptCode":"C16390","definition":"The cause of a disease or abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497F9A00-EA50-4A70-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBREXT","dateModified":"2008-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"497F9A00-EA61-4A70-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964872","version":"1","longName":"2000r1: Recipient Baseline Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":" PerformedClinicalInterpretation:value ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the cause of the the","type":"Preferred Question Text","description":"What was the cause of the therapy related AML?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2737648","type":"BRIDG Mapping Path","description":"PerformedDiagnosis [primary] > AssessedResultRelationship > PerformedObservation [etiology] > PerformedClinicalInterpretation.value(ANY=>DSET<CD>).item(CD).code WHERE  PerformedDiagnosis.value [primary] = \"Acute Myelogenous Leukemia (AML)\" AND AssessedResultRelationship.typeCode = \"etiology\" AND PerformedObservation > DefinedObservation.nameCode = \"determine etiology\" AND PerformedDiagnosis [primary] > PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Perform Overall Hemetopoietic Stem Cell Transplantation\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"497F9A00-EADD-4A70-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-28","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-28","modifiedBy":"KUMMEROA","dateModified":"2021-06-04","changeDescription":". 2021-6-4 ak System generated def displayed as alt def.  10/9/09mn-added c.s for F2000.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}